Inhibikase Therapeutics (IKT) Cash & Equivalents Growth (1y) (2021 - 2026)
Inhibikase Therapeutics (IKT) Cash & Equivalents Growth (1y) (2021 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Cash & Equiv. Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
762,369.55 Bn |
762,369.51 Bn |
- |
988.88% |
| 2 |
Belite Bio |
55,096.00 Bn |
55,096.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,755.80 Bn |
17,755.79 Bn |
- |
-68.22% |
| 4 |
Legend Biotech |
3,486.00 Bn |
3,485.71 Bn |
242.10 Mn |
0.00% |
| 5 |
Akari Therapeutics |
1,737.42 Bn |
1,737.41 Bn |
- |
4.77% |
| 6 |
Evaxion A |
1,551.28 Bn |
1,551.26 Bn |
- |
3.35% |
| 7 |
Psyence Biomedical |
227.32 Bn |
227.31 Bn |
- |
269.98% |
| 8 |
Vertex Pharmaceuticals |
110.84 Bn |
103.59 Bn |
2.59 Bn |
17.50% |
| 9 |
Abivax |
91.71 Bn |
91.71 Bn |
- |
- |
| 10 |
Inhibikase Therapeutics |
285.17 Mn |
114.80 Mn |
- |
-32.50% |
| Date | Value |
|---|
| Mar 31, 2026 |
-32.50% |
| Dec 31, 2025 |
146.45% |
| Sep 30, 2025 |
4,089.72% |
| Jun 30, 2025 |
2,418.83% |
| Mar 31, 2025 |
3,020.72% |
| Dec 31, 2024 |
516.36% |
| Sep 30, 2024 |
-93.85% |
| Jun 30, 2024 |
62.01% |
| Mar 31, 2024 |
-40.52% |
| Dec 31, 2023 |
27.50% |
| Sep 30, 2023 |
157.03% |
| Jun 30, 2023 |
-94.09% |
| Mar 31, 2023 |
-89.19% |
| Dec 31, 2022 |
-82.36% |
| Sep 30, 2022 |
-87.11% |
| Jun 30, 2022 |
-31.22% |
| Mar 31, 2022 |
280.98% |
| Dec 31, 2021 |
192.04% |
| Sep 30, 2021 |
277,274.75% |
| Jun 30, 2021 |
601,525.64% |
